COA Available
GLP-1 In Stock Research Use Only
Cagri + Reta
10mg · Lyophilized Powder · Purity ≥99%
Cagri + Reta is a co-formulated lyophilized research vial combining cagrilintide — a long-acting amylin/calcitonin receptor co-agonist — with retatrutide — a GLP-1, GIP and glucagon receptor triagonist — in a single 10 mg vial at ≥99% purity, supplied for multi-receptor metabolic signalling research.
$199.99 CAD
Purchase Options
Subscriptions can be managed from your customer account. Prices in CAD.
Research Overview
This combination research vial pairs two pharmacologically distinct metabolic research peptides in one co-lyophilized preparation: cagrilintide, a structurally stabilised amylin analogue acting as a dual AMY1R/AMY3R co-agonist, and retatrutide, a synthetic triagonist with simultaneous activity at the GLP-1, GIP and glucagon receptors. Together the two compounds span four receptor systems — amylin, GLP-1, GIP and glucagon — giving researchers a single-vial format for preclinical studies of concurrent amylin-pathway and incretin/glucagon-pathway engagement. Supplied exclusively for laboratory and research use — not for human or animal consumption.
Research interest in pairing an amylin receptor co-agonist with incretin-class agonists stems from preclinical work indicating that amylin signalling (area postrema and hypothalamic feeding circuits, gastric emptying) and GLP-1R/GIPR/GCGR signalling (insulin secretion, energy expenditure, hepatic lipid handling) regulate overlapping but mechanistically separate aspects of energy homeostasis. Investigational literature on amylin + GLP-1 combinations has examined whether engaging these pathways together produces additive metabolic signalling effects in experimental models; a triagonist partner extends that question to GIP and glucagon receptor pathways. All outcomes referenced pertain to preclinical or investigational models and do not constitute evidence of clinical efficacy or safety in humans.
Specifications
| Compound | Cagri + Reta |
| Format | Lyophilized Powder |
| Size | 10mg |
| Purity (HPLC) | ≥99% |
| Item # | BME-CAGRIR-A |
| Storage | −20°C, dry, dark |
| Price (CAD) | $199.99 |
COA / Testing
Batch documentation and third-party testing information are available for batch BME-CAGRIR-A. COA previews appear only when documentation exists for the active batch.
Storage & Handling
Store this lyophilized combination vial at −20°C in a sealed, moisture-free environment immediately upon receipt, protected from light. Avoid repeated freeze-thaw cycles; thermal cycling may affect the two components differently and compromise the consistency of research preparations. Reconstituted solutions should be prepared under sterile laboratory conditions and handled in accordance with your institution's standard operating procedures for research-grade peptide solutions.
Shipping & Returns
Orders are processed on business days. Packaging is selected to maintain compound integrity in transit. Shipping timelines and return conditions are outlined in full in the Shipping & Returns policy — review before checkout if you have specific requirements. For orders with time-sensitive research schedules, contact support before placing your order.
Research Use Disclaimer
This product is supplied strictly for in-vitro and laboratory research use. It is not a drug, food supplement, or cosmetic and is not approved for human or veterinary clinical applications, diagnostics, or therapeutic use. Researchers are responsible for compliance with all applicable institutional and regulatory requirements in their jurisdiction.
Preparation Reference Guide
Research Solution Reference Calculator
Pre-filled with 10mg. Enter your solvent volume and target amount to see concentration and units on a U-100 syringe scale.
Concentration—
Volume to draw—
Syringe units (U-100)—
Per insulin unit—
For research-use calculations only. Always verify measurements independently — not medical guidance.
Questions before you order?
Browse the FAQ for documentation, storage, and sourcing answers, or contact our support team directly. We aim to respond to all research procurement inquiries within one business day.
